About Synokem Pharmaceuticals Limited
Data last updated:
Synokem Pharmaceuticals Limited is a public limited company based in New Delhi, Delhi, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 18 August 1983 and has been in existence for over 43 years.
The company is registered with the Registrar of Companies (ROC), Delhi, under CIN U21002DL1983PLC016353. Its GSTIN is 07AAACS1164N1Z8 (Delhi). The company holds 6 GST registrations, of which 3 are active.
The company has an authorised share capital of ₹6 Cr and a paid-up capital of ₹4.82 Cr. It was formerly known as Synokem Pharmaceuticals Private Limited. It is led by directors including Abhinav Arora (Managing Director) and Gajanan Mohan Shenoy.
Its last annual general meeting (AGM) was held on 25 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at 14/486 Basement & Ground Floor, Outer Ring Road Paschim Vihar, New Delhi, Delhi, India – 110087.
As per the financials filed for FY 2025, the company reported a revenue of ₹556.24 Cr. For the same year it recorded a net loss of ₹3.28 Cr (net margin -0.6%) and EBITDA of ₹31.9 Cr (EBITDA margin 5.7%). Revenue has grown at a compounded annual rate (CAGR) of 5% over three years.
The company has about 363 employees on its provident fund (EPFO) records. Its group structure includes 3 subsidiaries.
The company is associated with 1 brand: Synokem Pharma. As per MCA filings, the company has open charges of ₹200 Cr and satisfied charges of ₹14.75 Cr on record. Court records list 91 cases involving the company, including 40 filed by the company and 53 filed against it; 27 cases are pending. The company has 11 deals on record (9 secondary share transfers, 2 funding rounds), with disclosed funding of ₹51.1 Lakh; the latest was in January 2023. Its 8 peer companies in the Pharma industry (Formulations, Pharmaceuticals), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products) are compared by revenue, 3 larger and 5 smaller; the largest is Bliss GVS Pharma Limited with revenue of ₹846.22 Cr. The company has 27 MSME Form 1 returns on record between 2019 and 2024, listing 4,861 overdue payments to 342 micro and small suppliers.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website synokempharma.com.
Company details
CIN history
Synokem Pharmaceuticals has one previous CIN (Corporate Identification Number): U34239DL1983PLC016353. The current CIN is U21002DL1983PLC016353, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| U21002DL1983PLC016353 | Current |
| U34239DL1983PLC016353 | Previous |
Contact details
Synokem Pharmaceuticals Limited's registered office is in New Delhi, Delhi. Its website is synokempharma.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Social Media
- Registered Address14/486 Basement & Ground Floor, Outer Ring Road Paschim Vihar, New Delhi, Delhi, India – 110087
- IndustryPharma, Drug Formulation & Development
To see the full contact details of Synokem Pharmaceuticals Limited, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Brands
Synokem Pharmaceuticals operates one associated brand: Synokem Pharma. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Generic drugs are manufactured by Synokem Pharma in Delhi. | synokempharma.com |
Business activity
The main business activity of Synokem Pharmaceuticals is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products |
To see the full business activity and turnover split of Synokem Pharmaceuticals Limited, buy the company report.
Financials of Synokem Pharmaceuticals Limited
FY 2025 filings availableSynokem Pharmaceuticals Limited reported revenue of ₹556.24 Cr for FY 2025.
Compounded Annual Growth Rate (CAGR)
Revenue has grown at a compounded annual rate (CAGR) of 5% over three years. EBITDA fell 49% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | ₹556.24 Cr | ||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | ₹31.9 Cr | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | -₹3.28 Cr | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 5.7% | ||||
| Net Profit Margin | -0.6% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Synokem Pharmaceuticals Limited, buy the company report.
Board of directors of Synokem Pharmaceuticals Limited
Synokem Pharmaceuticals has 8 current directors and 17 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Gajanan Mohan Shenoy | Director | 30 Mar 2024 | 2 Years 6 Months | Current |
| Vishal Gupta | Nominee Director | 18 Jan 2023 | 3 Years 9 Months | Current |
| Abhinav Arora Also directs: SPL Packaging Limited Liability Partnership, Kemsyn Lifesciences Private Limited, Synokem Lifesciences Private Limited and 2 more | Managing Director | 01 Jul 2005 | 21 Years 3 Months | Current |
| Thomas Baby | Director | 01 Jul 2019 | 7 Years 3 Months | Current |
| Shubhangi Agarwal Also directs: Synokem Lifesciences Private Limited, Agsa and Associates LLP, Ampl Capital Limited and 4 more | Director | 01 Apr 2022 | 4 Years 6 Months | Current |
| Dhiraj Poddar Also directs: Dough Hook Artisanal Bakery LLP, Omniactive Health Technologies Limited, Zifo Technologies Private Limited. and 3 more | Nominee Director | 24 Jul 2024 | 2 Years 2 Months | Current |
Peer comparison
Synokem Pharmaceuticals Limited is compared with the 8 companies closest to it by revenue in the Pharma industry (Formulations, Pharmaceuticals), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Bliss GVS Pharma Limited | ₹846.22 Cr (FY 2025) | 6.0% | Mumbai, Maharashtra, India | |||
| Apex Laboratories Private Limited | ₹834.88 Cr (FY 2025) | 7.0% | Chennai, Tamil Nadu, India | |||
| Gufic Biosciences Limited | ₹823.43 Cr (FY 2025) | 2.0% | Mumbai, Maharashtra, India | |||
| SMS Pharmaceuticals Limited | ₹788.97 Cr (FY 2025) | 11.0% | Hyderabad, Telangana, India | |||
| Prime Pharmaceuticals Private Limited | ₹783.06 Cr (FY 2025) | 131.0% | Mumbai, Maharashtra, India | |||
| Windlas Biotech Limited | ₹777.9 Cr (FY 2025) | 21.0% | Dehradun, Uttarakhand, India | |||
| Fourrts (India) Laboratories Private Limited | ₹760.55 Cr (FY 2024) | 7.0% | Chennai, Tamil Nadu, India | |||
| Pritam International Private Limited | ₹758.46 Cr (FY 2025) | 15.0% | Kolkata, West Bengal, India | |||
| Synokem Pharmaceuticals Limitedthis company | ₹556.24 Cr (FY 2025) | -₹3.28 Cr | -0.6% | 363 | New Delhi, Delhi, India |
To see the full peer comparison of Synokem Pharmaceuticals Limited, buy the company report.
Auditor
Synokem Pharmaceuticals Limited is audited by BSR & Co. LLP for the financial year 2025.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| BSR & Co. LLP | FY 2025 | 101248W/W-100022 |
Shareholding
The shareholding of Synokem Pharmaceuticals Limited is on record for 5 financial years, the latest being FY 2025, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Promoters | |||||
| Domestic institutional investors (DII) | |||||
| Foreign institutional investors (FII) | |||||
| Public | |||||
| Others |
To see the full shareholding pattern of Synokem Pharmaceuticals Limited, buy the company report.
Charges & borrowings
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 10 Mar 2026 | 101263462 | Others | ₹15 Cr | Open | |
| 31 Jul 2024 | 100961273 | Axis Bank Limited | ₹22.5 Cr | Open | |
| 06 May 2024 | 100920076 | Others | ₹15 Cr | Open | |
| 16 Jan 2024 | 100848505 | Others | ₹20 Cr | Open | |
| 22 Sep 2023 | 100791383 | Others | ₹115 Cr | Open |
To see the full charge records of Synokem Pharmaceuticals Limited, buy the company report.
Total charge records: 9 View all charges
Deals & funding
Synokem Pharmaceuticals Limited has 11 deals on record (9 secondary share transfers, 2 funding rounds), with disclosed funding of ₹51.1 Lakh; the latest was in January 2023.
Deals on record (5 of 11)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Jan 2023 | Secondary share transfer | Undisclosed | Seller: 3 individuals |
| Jan 2023 | Secondary share transfer | Undisclosed | Buyer: Ta India 2 Limited Seller: an individual |
| Jan 2023 | Secondary share transfer | Undisclosed | Buyer: Ta India 2 Limited, an individual Seller: 3 individuals |
| Nov 2022 | Secondary share transfer | Undisclosed | Buyer: Abhinav Arora Huf Seller: an individual |
| Dec 2020 | Secondary share transfer | Undisclosed | Buyer: an individual Seller: Jagmohan Arora HUF |
To see the full deal history of Synokem Pharmaceuticals Limited, buy the company report.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
Synokem Pharmaceuticals Limited has 91 court cases on record: 40 filed by Synokem Pharmaceuticals, 53 filed against it. 27 cases are pending and 64 are disposed.
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| District courts | 62 | 33 | 21 |
| High courts | 25 | 17 | 6 |
| Supreme Court | 4 | 3 | 0 |
Cases on record (5 of 91)
| Court | Type of case | Party | Status |
|---|---|---|---|
| Bombay High Court | Court case (LPETN) | Filed against the company by Sun Pharmaceutical Industries Limited | Pending |
| Bombay High Court | Court case (COMIP) | Filed against the company by Sun Pharmaceutical Industries Limited | Pending |
| District court, West, Delhi | Commercial suit | Filed by the company against M/S Starus Pharmaceuticals Private Limited | Pending |
| District court, West, Delhi | Commercial suit | Filed by the company against M/S Biomi Life Sciences Private Limited | Pending |
| High Court, MAHARASHTRA | Court case (COMIP) | Filed against the company by Sun Pharma Laboratories Limited | Pending |
To see the full case history of Synokem Pharmaceuticals Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
Credit ratings & regulatory alerts
Synokem Pharmaceuticals Limited was last rated by Crisil on 30 Oct 2019.
| Rating agency | Rated on | Rating |
|---|---|---|
| Crisil | 30 Oct 2019 |
To see the full credit ratings and regulatory alerts of Synokem Pharmaceuticals Limited, buy the company report.
MSME payment delays
Synokem Pharmaceuticals Limited has 27 MSME Form 1 returns on record between 2019 and 2024, listing 4,861 overdue payments to 342 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.
Suppliers with reported dues (5 of 342)
| Supplier | Amount due | Due since | Reported on |
|---|---|---|---|
| an individual supplier | |||
| A3a Infotech Private Limited | |||
| Wetec Engineering | |||
| Mex Storage Systems Pvt.L | |||
| Integrated Cooling Solutions Private Limited |
To see the full MSME payment records of Synokem Pharmaceuticals Limited, buy the company report.
Individuals and sole proprietors among the suppliers are not named.
Group structure & subsidiaries
Synokem Pharmaceuticals has 3 subsidiary companies. This group structure data is as of FY 2025. The table lists each entity with its relationship and holding.
| Company Name | CIN | Shares held |
|---|---|---|
| Kemsyn Lifesciences Private Limited | U21002MH2024PTC435803 | |
| Synokem Lifesciences Private Limited | U24230DL2020PTC362777 | |
| Nitin Lifesciences Limited | U73100HP2005PLC028049 |
To see the full group structure of Synokem Pharmaceuticals Limited, buy the company report.
Employees & EPFO
Synokem Pharmaceuticals Limited has a workforce of 363 employees on its EPFO records as of Oct 08, 2025, across 2 active EPFO establishments.
GST
Synokem Pharmaceuticals has 6 GST registrations: 3 active and 3 cancelled or inactive.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 07AAACS1164N1Z8 | Delhi | Active | 01 Jul 2017 |
| 07AAACS1164N2Z7 | Delhi | Active | 01 Apr 2025 |
| 05AAACS1164N1ZC | Uttarakhand | Active | 01 Jul 2017 |
To see the full GST registrations and return filing status of Synokem Pharmaceuticals Limited, buy the company report.
Recent activity
Synokem Pharmaceuticals Limited has 24 board changes on record since 2005: 9 appointments and 15 cessations. The latest: Yugal Kishor Chothuram Sikri was appointed as Nominee Director on 31 Jan 2026.
32 earlier events are in the company report.
Frequently asked questions
Synokem Pharmaceuticals is an active public limited company based in New Delhi, Delhi, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 18 August 1983 (43+ years old) and is registered under CIN U21002DL1983PLC016353.
Synokem Pharmaceuticals has 8 current directors:
- Abhinav Arora - Managing Director
- Gajanan Mohan Shenoy - Director
- Vishal Gupta - Nominee Director
- Thomas Baby - Director
- Shubhangi Agarwal - Director
- Dhiraj Poddar - Nominee Director
- Sanjay Khurana - Director
- Yugal Kishor Chothuram Sikri - Nominee Director
The latest financial statements of Synokem Pharmaceuticals on record with the MCA are for the year ended 31 March 2025. Its last annual general meeting was held on 25 September 2025. Year-wise statements from 2015 are in the company report.
The GSTIN of Synokem Pharmaceuticals is 07AAACS1164N1Z8, registered in Delhi. The company has 6 GST registrations in all, of which 3 are active and 3 are cancelled or inactive. Other active GSTINs include 07AAACS1164N2Z7 (Delhi), 05AAACS1164N1ZC (Uttarakhand).
The CIN (Corporate Identification Number) of Synokem Pharmaceuticals is U21002DL1983PLC016353. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Synokem Pharmaceuticals has 91 court cases on record: 40 filed by the company and 53 filed against it. 27 are pending. Most are in the district courts.
Synokem Pharmaceuticals was incorporated on 18 August 1983, making it 43+ years old. It is registered with the Registrar of Companies, Delhi.
Synokem Pharmaceuticals has 11 deals on record (9 secondary share transfers, 2 funding rounds), with disclosed funding of ₹51.1 Lakh; the latest was in January 2023.
The peers of Synokem Pharmaceuticals by revenue are Bliss GVS Pharma Limited, Apex Laboratories Private Limited, Gufic Biosciences Limited, SMS Pharmaceuticals Limited, Prime Pharmaceuticals Private Limited and 3 more, all in the Pharma industry (Formulations, Pharmaceuticals), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).
Yugal Kishor Chothuram Sikri was appointed as Nominee Director on 31 Jan 2026. Dhiraj Poddar was appointed as Nominee Director on 24 Jul 2024. Gajanan Mohan Shenoy ceased to be Additional Director on 07 Apr 2024. Synokem Pharmaceuticals has 24 board changes on record in total.
Synokem Pharmaceuticals has 27 MSME Form 1 returns on record between 2019 and 2024, listing 4,861 overdue payments to 342 micro and small suppliers. The latest return was filed on 17 May 2024.
Synokem Pharmaceuticals can be reached through the website synokempharma.com. Its registered office is in New Delhi, Delhi, India.